^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    RET rearrangement

    i
    Entrez ID:
    5979
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Apply
    Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy (ENDURE) (NCT04892953)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    07/07/2021
    Primary completion :
    09/30/2026
    Completion :
    09/30/2026
    EGFR • ALK • MET • RET • ROS1
    |
    RET fusion • ALK rearrangement • MET exon 14 mutation • ALK fusion • ROS1 fusion • ROS1 rearrangement • RET rearrangement
    |
    carboplatin • Imfinzi (durvalumab) • gemcitabine • albumin-bound paclitaxel • pemetrexed • Pemfexy (pemetrexed)
    Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial) (LUNG-MAP SUB-STUDY) (NCT06116682)
    Phase 2
    SWOG Cancer Research Network
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    11/19/2024
    Primary completion :
    05/31/2028
    Completion :
    05/31/2028
    EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK
    |
    BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • MET amplification • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement
    |
    Rybrevant (amivantamab-vmjw) • amivantamab SC (Ami-LC)
    Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial) (LUNG-MAP SUB-STUDY) (NCT06031688)
    Phase 2
    SWOG Cancer Research Network
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    08/08/2024
    Primary completion :
    05/31/2028
    Completion :
    05/31/2029
    EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK
    |
    BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement
    |
    Cyramza (ramucirumab) • Tepmetko (tepotinib)
    A Study of Avutometinib and Defactinib in People With Thyroid Cancer (NCT06007924)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    08/16/2023
    Primary completion :
    08/16/2027
    Completion :
    08/16/2027
    BRAF • ALK • RET • NF1 • NTRK
    |
    BRAF V600E • ALK rearrangement • BRAF V600K • RAS mutation • RET mutation • RET rearrangement
    |
    avutometinib (VS-6766) • defactinib (VS-6063)
    A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma (NCT05943795)
    Phase 3
    Sichuan Baili Pharmaceutical Co., Ltd.
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    07/14/2023
    Primary completion :
    07/01/2026
    Completion :
    07/01/2026
    EGFR • HER-2 • KRAS • BRAF • ALK • ROS1 • NTRK
    |
    KRAS mutation • KRAS G12C • BRAF mutation • HER-2 amplification • BRAF V600 • KRAS G12D • EGFR wild-type • RET mutation • ALK wild-type • ROS1 fusion • ROS1 rearrangement • RET rearrangement • KRAS G12 • KRAS amplification • NTRK fusion
    |
    docetaxel • izalontamab (SI-B001)
    Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer (NCT02299141)
    Phase 2
    Washington University School of Medicine
    Active, not recruiting
    Last update posted :
    02/11/2025
    Initiation :
    05/07/2015
    Primary completion :
    01/09/2020
    Completion :
    12/31/2025
    EGFR • ALK • TP53 • FLT1
    |
    EGFR mutation • ALK rearrangement • RET rearrangement
    |
    nintedanib
    Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer (NCT01708954)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    02/13/2013
    Primary completion :
    08/14/2015
    Completion :
    03/07/2025
    HER-2 • KRAS • BRAF • RET
    |
    KRAS mutation • EGFR mutation • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • RET mutation • RET rearrangement • EGFR L858R + EGFR exon 19 deletion
    |
    erlotinib • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors (ADVL1622) (NCT02867592)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/17/2024
    Initiation :
    05/18/2017
    Primary completion :
    06/30/2021
    Completion :
    09/21/2024
    MET • RET • AXL
    |
    MET amplification • MET overexpression • RET mutation • MET mutation • RET rearrangement • AXL overexpression
    |
    Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)
    SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer (NCT05570825)
    Phase 2
    University of Washington
    Recruiting
    Last update posted :
    05/07/2024
    Initiation :
    04/06/2023
    Primary completion :
    07/01/2027
    Completion :
    07/01/2028
    PD-L1 • ALK • RET • ROS1
    |
    PD-L1 expression • RET fusion • ALK rearrangement • ROS1 fusion • ROS1 rearrangement • RET rearrangement
    |
    Keytruda (pembrolizumab) • SX-682 • Pembroria (pembrolizumab biosimilar)
    Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW) (NCT03037385)
    Phase 1/2
    Hoffmann-La Roche
    Completed
    Last update posted :
    04/11/2024
    Initiation :
    03/17/2017
    Primary completion :
    03/21/2024
    Completion :
    03/21/2024
    RET
    |
    RET fusion • RET mutation • RET rearrangement
    |
    Gavreto (pralsetinib)
    A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer (NCT05949606)
    Phase 1/2
    Sichuan Baili Pharmaceutical Co., Ltd.
    Recruiting
    Last update posted :
    11/29/2023
    Initiation :
    10/30/2023
    Primary completion :
    11/01/2025
    Completion :
    11/01/2025
    HER-2 • KRAS • BRAF • ALK • MET • ROS1 • NTRK
    |
    BRAF mutation • BRAF V600 • EGFR wild-type • MET exon 14 mutation • ALK fusion • RET mutation • ROS1 fusion • ROS1 rearrangement • RET rearrangement • NTRK fusion
    |
    izalontamab (SI-B001) • danvilostomig (SI-B003)
    A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir) (NCT05788926)
    Phase 1
    Transgene
    Recruiting
    Last update posted :
    10/20/2023
    Initiation :
    04/05/2023
    Primary completion :
    10/30/2024
    Completion :
    03/31/2025
    EGFR • HER-2 • PD-L1 • KRAS • ALK • RET • ROS1
    |
    BRAF V600E • KRAS mutation • KRAS G12C • BRAF V600 • HER-2 mutation • RET fusion • RET mutation • ROS1 fusion • RET rearrangement • KRAS G12
    |
    TG6050
    Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer (NCT03468985)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    10/17/2023
    Initiation :
    05/07/2018
    Primary completion :
    05/09/2022
    Completion :
    12/21/2022
    EGFR • PD-L1 • ALK • RET • ROS1
    |
    EGFR L858R • EGFR exon 19 deletion • MET amplification • ALK rearrangement • MET exon 14 mutation • EGFR L861Q • EGFR G719X • RET rearrangement • EGFR negative
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar) • CMAB 819 (nivolumab biosimilar)
    A Study of DB-1311 in Advanced/Metastatic Solid Tumors (NCT05914116)
    Phase 1/2
    DualityBio Inc.
    Recruiting
    Last update posted :
    09/12/2023
    Initiation :
    09/05/2023
    Primary completion :
    04/01/2025
    Completion :
    04/01/2025
    EGFR • KRAS • BRAF • ALK • MET • ROS1 • NTRK1 • NTRK3 • NTRK2 • CD276
    |
    BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ALK rearrangement • MET exon 14 mutation • ROS1 rearrangement • MET mutation • RET rearrangement • KRAS G12 • NTRK1 mutation • NTRK3 mutation
    |
    BNT324
    Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers (NCT04712877)
    Phase N/A
    Lung Cancer Mutation Consortium
    Recruiting
    Last update posted :
    09/12/2023
    Initiation :
    06/15/2022
    Primary completion :
    06/15/2024
    Completion :
    06/15/2025
    EGFR • HER-2 • BRAF • ALK • TMB • MET • RET • ROS1 • NTRK
    |
    BRAF V600E • EGFR mutation • HER-2 amplification • BRAF V600 • MET amplification • ALK rearrangement • MET exon 14 mutation • RET mutation • ROS1 rearrangement • MET mutation • RET rearrangement • MET amplification + MET Exon 14 mutation
    OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer (NCT05935774)
    Phase 2
    University of Washington
    Withdrawn
    Last update posted :
    08/25/2023
    Initiation :
    12/01/2023
    Primary completion :
    07/31/2028
    Completion :
    07/31/2028
    HER-2 • BRAF • ALK • RET • ROS1 • CD4 • NTRK
    |
    BRAF mutation • HER-2 mutation • RET fusion • ALK rearrangement • ROS1 fusion • ROS1 rearrangement • RET rearrangement • NTRK fusion
    |
    Tecentriq (atezolizumab) • trabedersen (OT-101)
    A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies (APT-CUBE) (NCT05473156)
    Phase 1/2
    AP Biosciences Inc.
    Not yet recruiting
    Last update posted :
    02/03/2023
    Initiation :
    02/01/2023
    Primary completion :
    12/01/2026
    Completion :
    12/01/2027
    BRAF • MET • NTRK1 • NTRK3 • NTRK2
    |
    PD-L1 expression • BRAF V600E • BRAF V600 • NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • MET mutation • RET rearrangement • NTRK1 mutation • NTRK3 mutation
    |
    AP203
    LIquid BIopsies in Patients Presenting Non-small Cell Lung Cancer (LIBIL) (NCT02511288)
    Phase N/A
    Centre Leon Berard
    Recruiting
    Last update posted :
    10/08/2021
    Initiation :
    07/01/2015
    Primary completion :
    03/01/2026
    Completion :
    12/01/2026
    HER-2 • PD-L1 • BRAF • ALK • MET • ROS1
    |
    EGFR mutation • BRAF mutation • HER-2 mutation • MET amplification • RET rearrangement • ALK translocation
    Phase II Study With Cabozantinib in Patients With RET Positive NSCLC (CRETA) (NCT04131543)
    Phase 2
    University of Bologna
    Unknown status
    Last update posted :
    10/18/2019
    Initiation :
    08/07/2019
    Primary completion :
    08/07/2020
    Completion :
    08/07/2022
    RET
    |
    RET rearrangement
    |
    Cabometyx (cabozantinib tablet)
    Sunitinib in Never-Smokers With Lung Adenocarcinoma (NCT01829217)
    Phase 2
    Dana-Farber Cancer Institute
    Completed
    Last update posted :
    10/31/2018
    Initiation :
    05/01/2013
    Primary completion :
    08/01/2017
    Completion :
    01/01/2018
    EGFR • KRAS • ALK
    |
    KRAS mutation • EGFR mutation • ALK mutation • RET rearrangement
    |
    sunitinib
    Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer (NCT01502410)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    06/26/2018
    Initiation :
    01/01/2012
    Primary completion :
    06/01/2014
    Completion :
    06/01/2014
    RET • KDR • VEGFA
    |
    EGFR mutation • BRAF mutation • RET mutation • RET rearrangement
    |
    sorafenib